Global Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Regional Outlook and Forecast, 2024 - 2031
The Global Diabetic Neuropathy Treatment Market size is expected to reach $7.4 billion by 2031, rising at a market growth of 7.3% CAGR during the forecast period.
The demand for diabetic neuropathy treatment in North America is increasing due to several factors. Increasing diabetes prevalence in the region is among the primary factors. Thus, the North America region captured 39.5% revenue share in the market 2023. With high rates of smoking in Canada, there is a greater prevalence of diabetes and diabetic neuropathy among the population, leading to increased demand for this.
Advancements in treating diabetic neuropathy have made significant progress in recent years, offering patients a broader array of options to manage their condition effectively. One key area of advancement is pharmacological therapies. Novel medications have been developed that target specific pathways involved in nerve damage, such as inflammation and oxidative stress.
Additionally, as per the World Health Organization, the proportion of diabetic people among adults aged 18 years and older was 8.5% in 2014. Diabetes accounted for the direct cause of 1.5 million fatalities in 2019, with 48% of diabetes-related deaths occurring in individuals younger than 70 years of age. Diabetes accounted for an additional 460,000 fatalities due to kidney disease. Thus, the increasing prevalence of diabetes worldwide is a key driver of the market.
However, many people with diabetes may not be aware of the potential complications, including neuropathy, which can result from uncontrolled blood sugar levels over time. Such a lack of awareness may result in postponing the pursuit of medical attention upon the initial appearance of symptoms indicative of neuropathy, including numbness, tingling, or pain in the hands and feet. Hence, the lack of awareness of the disease may allow the adoption of treatments and hamper the market's growth.
By Distribution Channel Analysis
By distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment witnessed 47.8% revenue share in the market in 2023. Hospital pharmacies serve a vital function in furnishing patients with the proper medications prescribed for diabetic neuropathy.
By Drug Class Analysis
On the basis of drug class, the market is classified into capsaicin, opioid, non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, and others. The antidepressants segment recorded 29.3% revenue share in the market in 2022.
By Disorder Analysis
Based on disorder type, the market is characterized into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. The peripheral neuropathy segment garnered 63.8% revenue share in the market in 2023. There are many different causes of peripheral neuropathy, including diabetes, infections, exposure to toxins, and certain medications.
By Regional Analysis
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment acquired 26.9% revenue share in the market in 2023. Based on data from the International Diabetes Federation, this region is anticipated to have the highest prevalence of diabetes in 2021, with an estimated 191 million adults aged 20-79 affected.
List of Key Companies Profiled
- Abbott Laboratories
- Eli Lilly And Company
- Pfizer, Inc.
- Lupin Limited
- Astellas Pharma, Inc.
- Glenmark Pharmaceuticals Limited
- Boehringer Ingelheim International GmbH
- Novartis AG
- McKesson Corporation
- GlaxoSmithKline PLC (GSK)
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Others
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Antidepressants
- Opioid
- Capsaicin
- Others
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Global Diabetic Neuropathy Treatment Market, by Distribution Channel
- 1.4.2 Global Diabetic Neuropathy Treatment Market, by Drug Class
- 1.4.3 Global Diabetic Neuropathy Treatment Market, by Disorder Type
- 1.4.4 Global Diabetic Neuropathy Treatment Market, by Geography
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
- 3.3 Porter Five Forces Analysis
- Chapter 4. Global Diabetic Neuropathy Treatment Market by Distribution Channel
- 4.1 Global Hospitals Pharmacies Market by Region
- 4.2 Global Retail Pharmacies Market by Region
- 4.3 Global Others Market by Region
- Chapter 5. Global Diabetic Neuropathy Treatment Market by Drug Class
- 5.1 Global Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Region
- 5.2 Global Antidepressants Market by Region
- 5.3 Global Opioid Market by Region
- 5.4 Global Capsaicin Market by Region
- 5.5 Global Others Market by Region
- Chapter 6. Global Diabetic Neuropathy Treatment Market by Disorder Type
- 6.1 Global Peripheral Neuropathy Market by Region
- 6.2 Global Autonomic Neuropathy Market by Region
- 6.3 Global Proximal Neuropathy Market by Region
- 6.4 Global Focal Neuropathy Market by Region
- Chapter 7. Global Diabetic Neuropathy Treatment Market by Region
- 7.1 North America Diabetic Neuropathy Treatment Market
- 7.1.1 North America Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.1.1.1 North America Hospitals Pharmacies Market by Country
- 7.1.1.2 North America Retail Pharmacies Market by Country
- 7.1.1.3 North America Others Market by Country
- 7.1.2 North America Diabetic Neuropathy Treatment Market by Drug Class
- 7.1.2.1 North America Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
- 7.1.2.2 North America Antidepressants Market by Country
- 7.1.2.3 North America Opioid Market by Country
- 7.1.2.4 North America Capsaicin Market by Country
- 7.1.2.5 North America Others Market by Country
- 7.1.3 North America Diabetic Neuropathy Treatment Market by Disorder Type
- 7.1.3.1 North America Peripheral Neuropathy Market by Country
- 7.1.3.2 North America Autonomic Neuropathy Market by Country
- 7.1.3.3 North America Proximal Neuropathy Market by Country
- 7.1.3.4 North America Focal Neuropathy Market by Country
- 7.1.4 North America Diabetic Neuropathy Treatment Market by Country
- 7.1.4.1 US Diabetic Neuropathy Treatment Market
- 7.1.4.1.1 US Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.1.4.1.2 US Diabetic Neuropathy Treatment Market by Drug Class
- 7.1.4.1.3 US Diabetic Neuropathy Treatment Market by Disorder Type
- 7.1.4.2 Canada Diabetic Neuropathy Treatment Market
- 7.1.4.2.1 Canada Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.1.4.2.2 Canada Diabetic Neuropathy Treatment Market by Drug Class
- 7.1.4.2.3 Canada Diabetic Neuropathy Treatment Market by Disorder Type
- 7.1.4.3 Mexico Diabetic Neuropathy Treatment Market
- 7.1.4.3.1 Mexico Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.1.4.3.2 Mexico Diabetic Neuropathy Treatment Market by Drug Class
- 7.1.4.3.3 Mexico Diabetic Neuropathy Treatment Market by Disorder Type
- 7.1.4.4 Rest of North America Diabetic Neuropathy Treatment Market
- 7.1.4.4.1 Rest of North America Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.1.4.4.2 Rest of North America Diabetic Neuropathy Treatment Market by Drug Class
- 7.1.4.4.3 Rest of North America Diabetic Neuropathy Treatment Market by Disorder Type
- 7.2 Europe Diabetic Neuropathy Treatment Market
- 7.2.1 Europe Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.1.1 Europe Hospitals Pharmacies Market by Country
- 7.2.1.2 Europe Retail Pharmacies Market by Country
- 7.2.1.3 Europe Others Market by Country
- 7.2.2 Europe Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.2.1 Europe Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
- 7.2.2.2 Europe Antidepressants Market by Country
- 7.2.2.3 Europe Opioid Market by Country
- 7.2.2.4 Europe Capsaicin Market by Country
- 7.2.2.5 Europe Others Market by Country
- 7.2.3 Europe Diabetic Neuropathy Treatment Market by Disorder Type
- 7.2.3.1 Europe Peripheral Neuropathy Market by Country
- 7.2.3.2 Europe Autonomic Neuropathy Market by Country
- 7.2.3.3 Europe Proximal Neuropathy Market by Country
- 7.2.3.4 Europe Focal Neuropathy Market by Country
- 7.2.4 Europe Diabetic Neuropathy Treatment Market by Country
- 7.2.4.1 Germany Diabetic Neuropathy Treatment Market
- 7.2.4.1.1 Germany Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.4.1.2 Germany Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.4.1.3 Germany Diabetic Neuropathy Treatment Market by Disorder Type
- 7.2.4.2 UK Diabetic Neuropathy Treatment Market
- 7.2.4.2.1 UK Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.4.2.2 UK Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.4.2.3 UK Diabetic Neuropathy Treatment Market by Disorder Type
- 7.2.4.3 France Diabetic Neuropathy Treatment Market
- 7.2.4.3.1 France Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.4.3.2 France Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.4.3.3 France Diabetic Neuropathy Treatment Market by Disorder Type
- 7.2.4.4 Russia Diabetic Neuropathy Treatment Market
- 7.2.4.4.1 Russia Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.4.4.2 Russia Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.4.4.3 Russia Diabetic Neuropathy Treatment Market by Disorder Type
- 7.2.4.5 Spain Diabetic Neuropathy Treatment Market
- 7.2.4.5.1 Spain Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.4.5.2 Spain Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.4.5.3 Spain Diabetic Neuropathy Treatment Market by Disorder Type
- 7.2.4.6 Italy Diabetic Neuropathy Treatment Market
- 7.2.4.6.1 Italy Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.4.6.2 Italy Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.4.6.3 Italy Diabetic Neuropathy Treatment Market by Disorder Type
- 7.2.4.7 Rest of Europe Diabetic Neuropathy Treatment Market
- 7.2.4.7.1 Rest of Europe Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.4.7.2 Rest of Europe Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.4.7.3 Rest of Europe Diabetic Neuropathy Treatment Market by Disorder Type
- 7.3 Asia Pacific Diabetic Neuropathy Treatment Market
- 7.3.1 Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.1.1 Asia Pacific Hospitals Pharmacies Market by Country
- 7.3.1.2 Asia Pacific Retail Pharmacies Market by Country
- 7.3.1.3 Asia Pacific Others Market by Country
- 7.3.2 Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.2.1 Asia Pacific Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
- 7.3.2.2 Asia Pacific Antidepressants Market by Country
- 7.3.2.3 Asia Pacific Opioid Market by Country
- 7.3.2.4 Asia Pacific Capsaicin Market by Country
- 7.3.2.5 Asia Pacific Others Market by Country
- 7.3.3 Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type
- 7.3.3.1 Asia Pacific Peripheral Neuropathy Market by Country
- 7.3.3.2 Asia Pacific Autonomic Neuropathy Market by Country
- 7.3.3.3 Asia Pacific Proximal Neuropathy Market by Country
- 7.3.3.4 Asia Pacific Focal Neuropathy Market by Country
- 7.3.4 Asia Pacific Diabetic Neuropathy Treatment Market by Country
- 7.3.4.1 China Diabetic Neuropathy Treatment Market
- 7.3.4.1.1 China Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.4.1.2 China Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.4.1.3 China Diabetic Neuropathy Treatment Market by Disorder Type
- 7.3.4.2 Japan Diabetic Neuropathy Treatment Market
- 7.3.4.2.1 Japan Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.4.2.2 Japan Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.4.2.3 Japan Diabetic Neuropathy Treatment Market by Disorder Type
- 7.3.4.3 India Diabetic Neuropathy Treatment Market
- 7.3.4.3.1 India Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.4.3.2 India Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.4.3.3 India Diabetic Neuropathy Treatment Market by Disorder Type
- 7.3.4.4 South Korea Diabetic Neuropathy Treatment Market
- 7.3.4.4.1 South Korea Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.4.4.2 South Korea Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.4.4.3 South Korea Diabetic Neuropathy Treatment Market by Disorder Type
- 7.3.4.5 Australia Diabetic Neuropathy Treatment Market
- 7.3.4.5.1 Australia Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.4.5.2 Australia Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.4.5.3 Australia Diabetic Neuropathy Treatment Market by Disorder Type
- 7.3.4.6 Malaysia Diabetic Neuropathy Treatment Market
- 7.3.4.6.1 Malaysia Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.4.6.2 Malaysia Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.4.6.3 Malaysia Diabetic Neuropathy Treatment Market by Disorder Type
- 7.3.4.7 Rest of Asia Pacific Diabetic Neuropathy Treatment Market
- 7.3.4.7.1 Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.4.7.2 Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.4.7.3 Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type
- 7.4 LAMEA Diabetic Neuropathy Treatment Market
- 7.4.1 LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.1.1 LAMEA Hospitals Pharmacies Market by Country
- 7.4.1.2 LAMEA Retail Pharmacies Market by Country
- 7.4.1.3 LAMEA Others Market by Country
- 7.4.2 LAMEA Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.2.1 LAMEA Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
- 7.4.2.2 LAMEA Antidepressants Market by Country
- 7.4.2.3 LAMEA Opioid Market by Country
- 7.4.2.4 LAMEA Capsaicin Market by Country
- 7.4.2.5 LAMEA Others Market by Country
- 7.4.3 LAMEA Diabetic Neuropathy Treatment Market by Disorder Type
- 7.4.3.1 LAMEA Peripheral Neuropathy Market by Country
- 7.4.3.2 LAMEA Autonomic Neuropathy Market by Country
- 7.4.3.3 LAMEA Proximal Neuropathy Market by Country
- 7.4.3.4 LAMEA Focal Neuropathy Market by Country
- 7.4.4 LAMEA Diabetic Neuropathy Treatment Market by Country
- 7.4.4.1 Brazil Diabetic Neuropathy Treatment Market
- 7.4.4.1.1 Brazil Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.4.1.2 Brazil Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.4.1.3 Brazil Diabetic Neuropathy Treatment Market by Disorder Type
- 7.4.4.2 Argentina Diabetic Neuropathy Treatment Market
- 7.4.4.2.1 Argentina Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.4.2.2 Argentina Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.4.2.3 Argentina Diabetic Neuropathy Treatment Market by Disorder Type
- 7.4.4.3 UAE Diabetic Neuropathy Treatment Market
- 7.4.4.3.1 UAE Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.4.3.2 UAE Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.4.3.3 UAE Diabetic Neuropathy Treatment Market by Disorder Type
- 7.4.4.4 Saudi Arabia Diabetic Neuropathy Treatment Market
- 7.4.4.4.1 Saudi Arabia Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.4.4.2 Saudi Arabia Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.4.4.3 Saudi Arabia Diabetic Neuropathy Treatment Market by Disorder Type
- 7.4.4.5 South Africa Diabetic Neuropathy Treatment Market
- 7.4.4.5.1 South Africa Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.4.5.2 South Africa Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.4.5.3 South Africa Diabetic Neuropathy Treatment Market by Disorder Type
- 7.4.4.6 Nigeria Diabetic Neuropathy Treatment Market
- 7.4.4.6.1 Nigeria Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.4.6.2 Nigeria Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.4.6.3 Nigeria Diabetic Neuropathy Treatment Market by Disorder Type
- 7.4.4.7 Rest of LAMEA Diabetic Neuropathy Treatment Market
- 7.4.4.7.1 Rest of LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.4.7.2 Rest of LAMEA Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.4.7.3 Rest of LAMEA Diabetic Neuropathy Treatment Market by Disorder Type
- Chapter 8. Company Profiles
- 8.1 Abbott Laboratories
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Segmental and Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 Recent strategies and developments:
- 8.1.5.1 Acquisition and Mergers:
- 8.1.5.2 Trial and Approval:
- 8.1.6 SWOT Analysis
- 8.2 Eli Lilly And Company
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expenses
- 8.2.5 Recent strategies and developments:
- 8.2.5.1 Acquisition and Mergers:
- 8.2.6 SWOT Analysis
- 8.3 Pfizer, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional & Segmental Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 SWOT Analysis
- 8.4 Lupin Limited
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expense
- 8.4.5 SWOT Analysis
- 8.5 Astellas Pharma, Inc.
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Regional Analysis
- 8.5.4 Research & Development Expense
- 8.5.5 SWOT Analysis
- 8.6 Glenmark Pharmaceuticals Limited
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Regional Analysis
- 8.6.4 Research & Development Expenses
- 8.6.5 SWOT Analysis
- 8.7 Boehringer Ingelheim International GmbH
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Regional & Segmental Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 SWOT Analysis
- 8.8 Novartis AG
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
- 8.8.5.1 Acquisition and Mergers:
- 8.8.6 SWOT Analysis
- 8.9 McKesson Corporation
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental Analysis
- 8.9.4 Research & Development Expense
- 8.9.5 SWOT Analysis
- 8.10. GlaxoSmithKline PLC (GSK)
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional Analysis
- 8.10.4 Research & Development Expense
- 8.10.5 SWOT Analysis
- Chapter 9. Winning Imperatives of Diabetic Neuropathy Treatment Market
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook